在国家阿尔茨海默氏症协调中心数据库中对TDP-43神经病理学数据的综合评估
Davis C Woodworth1,2, Katelynn M Nguyen1,2, Lorena Sordo2,3
1Department of Neurology, University of California, Irvine, Office 364, Med Surge II Building, Irvine, CA, 92697, USA.
Acta neuropathologica
|June 19, 2024
概括
在像FTLD-TDP和ALS-TDP这样的神经退行性疾病中,TDP-43蛋白质病变很常见. 这项研究分析了TDP-43数据,发现了不同TDP-43病理和痴呆症,阿尔茨海默氏症和前性痴呆症之间的关联.
科学领域:
- 神经病理学神经病理学
- 神经退行性疾病 神经退行性疾病
- TDP-43 蛋白质异常症 蛋白质异常症
背景情况:
- TDP-43蛋白病变是前叶退化 (FTLD-TDP),肌缩侧面硬化 (ALS-TDP) 和边缘主导的与年龄有关的TDP-43脑病变神经病理变化 (LATE-NC) 的关键特征.
- 这些情况通常与衰老的海马硬化症 (HS-A) 相关.
研究的目的:
- 在国家阿尔茨海默氏症协调中心 (NACC) 数据库中评估TDP-43相关病理学评估的可用性.
- 检查不同TDP-43病理,临床诊断和其他神经病理之间的关联.
主要方法:
- 分析了NACC数据库中的4326名参与者的神经病理学数据.
- 评估TDP-43评估的可用性和区域分布.
- 对2142名参与者的协会进行统计分析,并提供完整的TDP-43数据.
主要成果:
- TDP-43评估的可用性各不相同,HS-A (97%) 和ALS (94%) 是最高的.
- 在具有完整数据的参与者中,LATE-NC (27%) 和ALS/FTLD-TDP (9%) 被确定.
- 所有TDP-43病理与更高的痴呆,HS-A和海马缩的几率有关.
结论:
- 包括LATE-NC和ALS/FTLD-TDP在内的TDP-43病理与痴呆和特定的神经病理变化有关.
- 在使用NACC数据时,研究人员必须考虑数据的可用性和各种TDP-43病理的患病率.
- 这些发现突出了TDP-43蛋白质病变和其他神经退行性疾病之间的复杂相互作用.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.肌缩性侧面硬化症 (AMLS) 是一种疾病.痴呆症是一种痴呆症.前側葉退化 前側葉退化衰老的海马硬化症的衰老.边缘主导性与年龄相关的TDP-43脑病变神经病理变化国家阿尔茨海默氏症协调中心在TDP-43中使用.更多相关视频
11:03Use of Capillary Electrophoresis Immunoassay to Search for Potential Biomarkers of Amyotrophic Lateral Sclerosis in Human Platelets
Published on: February 10, 2020
7.3K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.9K
相关概念视频
01:26Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
01:22Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
01:30Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110